Burling Wealth Partners LLC Sells 154 Shares of Amgen Inc. (NASDAQ:AMGN)

Burling Wealth Partners LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 16.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 775 shares of the medical research company’s stock after selling 154 shares during the quarter. Burling Wealth Partners LLC’s holdings in Amgen were worth $241,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of AMGN. First Pacific Financial lifted its position in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67 shares during the period. Pinney & Scofield Inc. acquired a new position in Amgen during the fourth quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Global Wealth Strategies & Associates raised its holdings in shares of Amgen by 1,388.9% during the 1st quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company’s stock worth $42,000 after buying an additional 125 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the 4th quarter worth $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 0.3%

NASDAQ:AMGN opened at $298.25 on Friday. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $160.37 billion, a PE ratio of 27.21, a PEG ratio of 2.70 and a beta of 0.49. The firm has a 50-day moving average of $285.32 and a 200-day moving average of $288.91.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period in the previous year, the company posted $3.96 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Mizuho lifted their price target on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research note on Wednesday, May 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $307.82.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.